Correction for Gotto and Kuller, Circulation 105 (2) 136-139.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

(Circulation. 2002;105:1146.)
© 2002 American Heart Association, Inc.

Editor’s Clarification of Statement of Conflict of Interest by Dr Antonio M. Gotto, Jr (Circulation. 2002;105:136–139)

In the Editorial titled, "Eligibility for Lipid-Lowering Drug Therapy in Primary Prevention," (Circulation. 2002;105:136–139), written by Drs Antonio M. Gotto and Lewis H. Kuller, Dr Gotto indicated in the published Acknowledgment that he had received support from Merck & Co, Inc, for his contribution to the Editorial. In response to a question about this financial disclosure, the Editor wishes to clarify it for Dr Gotto.

Dr Gotto was indicating that he receives an honorarium from Merck & Co, Inc, in support of his research, writing, lecturing, and scholarly activities. He received no direct financial support for writing the Editorial in Circulation.